Merrilee Needham, Mbbs, Fracp

List of Publications by Year
in descending order

44 papers	1,898 citations	361413 20 h-index	276875 41 g-index
48 all docs	48 docs citations	48 times ranked	1956 citing authors

#	Article	IF	Citations
1	Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurology, The, 2007, 6, 620-631.	10.2	239
2	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
3	Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular Disorders, 2007, 17, 194-200.	0.6	217
4	Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology, 2014, 83, 426-433.	1.1	192
5	Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. Journal of Clinical Neuroscience, 2008, 15, 1350-1353.	1.5	126
6	Necrotizing autoimmune myopathy. Current Opinion in Rheumatology, 2011, 23, 612-619.	4.3	118
7	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
8	Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology, 2016, 127, 1764-1773.	1.5	59
9	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
10	A Systematic Review and Meta-Analysis ofÂPrevalence Studies of Sporadic Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 127-137.	2.6	49
11	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open, 2016, 6, e012054.	1.9	48
12	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	2.6	44
13	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
14	Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. Journal of Clinical Neuroscience, 2015, 22, 6-13.	1.5	40
15	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiology of Aging, 2016, 47, 218.e1-218.e9.	3.1	40
16	Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience, 2021, 13, 658226.	3.4	38
17	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
18	Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective. Neuromuscular Disorders, 2016, 26, 734-740.	0.6	32

#	Article	IF	Citations
19	Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscular Disorders, 2014, 24, 1036-1041.	0.6	29
20	Idiopathic inflammatory myopathies: a review. Internal Medicine Journal, 2021, 51, 845-852.	0.8	28
21	Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges . International Journal of General Medicine, 2019, Volume 12, 465-474.	1.8	22
22	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999.	3.7	18
23	Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. European Journal of Human Genetics, 2022, 30, 532-539.	2.8	16
24	Apolipoprotein Îµ alleles in sporadic inclusion body myositis: A reappraisal. Neuromuscular Disorders, 2008, 18, 150-152.	0.6	15
25	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. Genome Medicine, 2022, 14, 7.	8.2	12
26	Immunotherapies for Immune-Mediated Myopathies: A Current Perspective. Neurotherapeutics, 2016, 13, 132-146.	4.4	11
27	Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: A pilot study. Neuromuscular Disorders, 2020, 30, 294-300.	0.6	8
28	Imaging in the diagnosis of idiopathic inflammatory myopathies; indications and utility. Expert Review of Neurotherapeutics, 2019, 19, 173-184.	2.8	7
29	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. Seminars in Arthritis and Rheumatism, 2020, 50, 943-948.	3.4	6
30	Evaluation of an Australian neurological nurseâ€led model of postdischarge care. Health and Social Care in the Community, 2022, 30, .	1.6	5
31	Is it Pompe Disease? Australian diagnostic considerations. Neuromuscular Disorders, 2020, 30, 389-399.	0.6	4
32	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.7	4
33	Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects. Expert Opinion on Orphan Drugs, 2017, 5, 431-443.	0.8	3
34	Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal Medicine Journal, 2022, 52, 110-120.	0.8	3
35	Prominent scapulae mimicking an inherited myopathy expands the phenotype of CHD7-related disease. European Journal of Human Genetics, 2016, 24, 1216-1219.	2.8	2
36	Clinical Utility Gene Card for: Becker muscular dystrophy. European Journal of Human Genetics, 2018, 26, 1065-1071.	2.8	2

#	Article	IF	Citations
37	Isolation of Live Leukocytes from Human Inflammatory Muscles. Methods and Protocols, 2021, 4, 75.	2.0	2
38	Acute spontaneous spinal cord infarction: Utilisation of hyperbaric oxygen treatment, cerebrospinal fluid drainage and pentoxifylline. Diving and Hyperbaric Medicine, 2020, 50, 325-331.	0.5	2
39	Primary lateral sclerosis-like picture in a patient with a remote history of anti-N-methyl-D- aspartate receptor (anti-NMDAR) antibody encephalitis. BMJ Case Reports, 2018, 2018, bcr-2017-224060.	0.5	1
40	Clinical Utility Gene Card for: autosomal dominant myotonia congenita (Thomsen Disease). European Journal of Human Genetics, 2018, 26, 1072-1077.	2.8	1
41	Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. Journal of Clinical Neuromuscular Disease, 2020, 21, 246-247.	0.7	1
42	078â€…Sensory nerve abnormalities in motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A25.1-A25.	1.9	0
43	Investigation of hereditary muscle disorders in the genomic era. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 17-20.	0.1	0
44	Expanding the MYOD1 phenotype: A case report of a patient diagnosed whilst pregnant. Journal of Neuromuscular Diseases, 2022, , 1-4.	2.6	0